We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00138866
First Posted: August 30, 2005
Last Update Posted: October 13, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The Physicians' Services Incorporated Foundation
St. Joseph's Health Care London
Information provided by:
Toronto Rehabilitation Institute
August 29, 2005
August 30, 2005
October 13, 2010
November 2004
January 2009   (Final data collection date for primary outcome measure)
Change in bone mineral density of the distal femur between baseline and 18-months [ Time Frame: 18 months ]
Change in bone mineral density of the distal femur between baseline and 18-months.
Complete list of historical versions of study NCT00138866 on ClinicalTrials.gov Archive Site
  • Change in bone mineral density of the hips and proximal tibia between baseline and 18-months [ Time Frame: 18 months ]
  • The change in biochemical bone markers of bone turnover between baseline and 18-months [ Time Frame: 18 months ]
  • The frequency and severity of adverse events [ Time Frame: 18 months ]
  • Change in bone mineral density of the hips and proximal tibia between baseline and 18-months.
  • The change in biochemical bone markers of bone turnover between baseline and 18-months.
  • The frequency and severity of adverse events.
Not Provided
Not Provided
 
Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury
Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury
The purpose of this study is to find out if risedronate works for the treatment of osteoporosis for people with spinal cord injury.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Osteoporosis
Drug: Risedronate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
March 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Traumatic spinal cord injury of greater than 18 months
  • Osteopenia or osteoporosis of the hip
  • Must be able to swallow tablets and sit upright

Exclusion Criteria:

  • Bilateral heterotopic ossification
  • Bilateral lower extremity metal implants
  • Pregnant or lactating females
  • Paget's disease
  • Osteomalacia
  • Steroid induced bone loss
  • Untreated parathyroid or thyroid disease
  • Symptomatic hypocalcemia or hypophosphatemia
  • Treatment in the last year with calcitonin, fluoride or anabolic steroids
  • Current treatment with prednisone
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00138866
TRI REB #04-016
PSI #03-52
Yes
Not Provided
Not Provided
Dr. BC Craven, Toronto Rehab Institute
Toronto Rehabilitation Institute
  • The Physicians' Services Incorporated Foundation
  • St. Joseph's Health Care London
Principal Investigator: B. Cathy Craven, MD, FRCPC Toronto Rehabilitation Institute
Toronto Rehabilitation Institute
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP